골다공증 치료약

소개

골다공증 치료약 정리 파일입니다

목차

NAMS recommends adding osteoporosis drug therapy
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Etidronate
Adverse Events with Bisphosphonate Therapy
Long-term Safety of Bisphosphonate Therapy
Discontinuation of Bisphosphonate Therapy
Selective Estrogen-receptor Modulators
Parathyroid Hormone
Estrogens
BMD
Fracture
Therapy Management
Discontinuation of Therapy
Calcitonin
Combination Therapies
Tibolone
Promising New Therapies
Strontium Ranelate
Parathyroid Hormone 1–84
Bazedoxifene
Lasofoxifene
Denosumab
RECOMMENDATIONS

본문내용

NAMS recommends adding osteoporosis drug therapy
All postmenopausal women who have had an osteoporotic vertebral or hip fracture.
All postmenopausal women who have BMD values consistent with osteoporosis at the lumbar spine, femoral neck, or total hip region.
All postmenopausal women who have T-scores from 1.0 to 2.5 and a 10-year risk of major osteoporotic fracture of at least 20% or of hip fracture of at least 3%.

---------------------------<중략>---------------------------

Combination Therapies
Combined alendronate and ET, risedronate and ET/EPT → more BMD improvements
Combining antiresorptive agents is not generally recommended
Significant increases in BMD occurred when teriparatide was added to ongoing ET
Combined PTH 184 and alendronate → less BMD response than PTH alone

참고자료

· 없음